182 related articles for article (PubMed ID: 37371622)
1. Metabolomic Investigation of Blood and Urinary Amino Acids and Derivatives in Patients with Type 2 Diabetes Mellitus and Early Diabetic Kidney Disease.
Mogos M; Socaciu C; Socaciu AI; Vlad A; Gadalean F; Bob F; Milas O; Cretu OM; Suteanu-Simulescu A; Glavan M; Ienciu S; Balint L; Jianu DC; Petrica L
Biomedicines; 2023 May; 11(6):. PubMed ID: 37371622
[TBL] [Abstract][Full Text] [Related]
2. Metabolite Profiling of the Gut-Renal-Cerebral Axis Reveals a Particular Pattern in Early Diabetic Kidney Disease in T2DM Patients.
Balint L; Socaciu C; Socaciu AI; Vlad A; Gadalean F; Bob F; Milas O; Cretu OM; Suteanu-Simulescu A; Glavan M; Ienciu S; Mogos M; Jianu DC; Petrica L
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047187
[TBL] [Abstract][Full Text] [Related]
3. Metabolomic Profiling of Amino Acids in Human Plasma Distinguishes Diabetic Kidney Disease From Type 2 Diabetes Mellitus.
Zhou C; Zhang Q; Lu L; Wang J; Liu D; Liu Z
Front Med (Lausanne); 2021; 8():765873. PubMed ID: 34912824
[No Abstract] [Full Text] [Related]
4. Quantitative, Targeted Analysis of Gut Microbiota Derived Metabolites Provides Novel Biomarkers of Early Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients.
Balint L; Socaciu C; Socaciu AI; Vlad A; Gadalean F; Bob F; Milas O; Cretu OM; Suteanu-Simulescu A; Glavan M; Ienciu S; Mogos M; Jianu DC; Petrica L
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509122
[TBL] [Abstract][Full Text] [Related]
5. Metabolomic Signature of Diabetic Kidney Disease in Cerebrospinal Fluid and Plasma of Patients with Type 2 Diabetes Using Liquid Chromatography-Mass Spectrometry.
Lin HT; Cheng ML; Lo CJ; Lin G; Liu FC
Diagnostics (Basel); 2022 Oct; 12(11):. PubMed ID: 36359470
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic profiling of amino acids study reveals a distinct diagnostic model for diabetic kidney disease.
Wang J; Zhou C; Zhang Q; Liu Z
Amino Acids; 2023 Nov; 55(11):1563-1572. PubMed ID: 37736814
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of UbA52 level in the urine of patients with type 2 diabetes mellitus and diabetic kidney disease.
Xu X; Dong Y; Liu M; Li Y; Zhang Y
Nefrologia (Engl Ed); 2021; 41(5):548-555. PubMed ID: 36165137
[TBL] [Abstract][Full Text] [Related]
8. UPLC-MS-based urine nontargeted metabolic profiling identifies dysregulation of pantothenate and CoA biosynthesis pathway in diabetic kidney disease.
Ma T; Liu T; Xie P; Jiang S; Yi W; Dai P; Guo X
Life Sci; 2020 Oct; 258():118160. PubMed ID: 32730837
[TBL] [Abstract][Full Text] [Related]
9. Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease.
Luo M; Zhang Z; Lu Y; Feng W; Wu H; Fan L; Guan B; Dai Y; Tang D; Dong X; Yun C; Hocher B; Liu H; Li Q; Yin L
Int Urol Nephrol; 2023 Apr; 55(4):1001-1013. PubMed ID: 36255506
[TBL] [Abstract][Full Text] [Related]
10. Metabolomic biomarkers in diabetic kidney diseases--A systematic review.
Zhang Y; Zhang S; Wang G
J Diabetes Complications; 2015; 29(8):1345-51. PubMed ID: 26253264
[TBL] [Abstract][Full Text] [Related]
11. Novel biomarkers for prognosticating diabetic kidney disease progression.
Swaminathan SM; Rao IR; Shenoy SV; Prabhu AR; Mohan PB; Rangaswamy D; Bhojaraja MV; Nagri SK; Nagaraju SP
Int Urol Nephrol; 2023 Apr; 55(4):913-928. PubMed ID: 36271990
[TBL] [Abstract][Full Text] [Related]
12. Targeted metabolomics as a tool for the diagnosis of kidney disease in Type II diabetes mellitus.
Abdelsattar S; Kasemy ZA; Elsayed M; Elrahem TA; Zewain SK
Br J Biomed Sci; 2021 Oct; 78(4):184-190. PubMed ID: 33656967
[No Abstract] [Full Text] [Related]
13. Optimization of kidney dysfunction prediction in diabetic kidney disease using targeted metabolomics.
Ibarra-González I; Cruz-Bautista I; Bello-Chavolla OY; Vela-Amieva M; Pallares-Méndez R; Ruiz de Santiago Y Nevarez D; Salas-Tapia MF; Rosas-Flota X; González-Acevedo M; Palacios-Peñaloza A; Morales-Esponda M; Aguilar-Salinas CA; Del Bosque-Plata L
Acta Diabetol; 2018 Nov; 55(11):1151-1161. PubMed ID: 30173364
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study.
Kwan B; Fuhrer T; Zhang J; Darshi M; Van Espen B; Montemayor D; de Boer IH; Dobre M; Hsu CY; Kelly TN; Raj DS; Rao PS; Saraf SL; Scialla J; Waikar SS; Sharma K; Natarajan L;
Am J Kidney Dis; 2020 Oct; 76(4):511-520. PubMed ID: 32387023
[TBL] [Abstract][Full Text] [Related]
15. Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study.
Zhang H; Zuo JJ; Dong SS; Lan Y; Wu CW; Mao GY; Zheng C
J Diabetes Res; 2020; 2020():3049098. PubMed ID: 32190695
[TBL] [Abstract][Full Text] [Related]
16. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study).
van der Kloet FM; Tempels FW; Ismail N; van der Heijden R; Kasper PT; Rojas-Cherto M; van Doorn R; Spijksma G; Koek M; van der Greef J; Mäkinen VP; Forsblom C; Holthöfer H; Groop PH; Reijmers TH; Hankemeier T
Metabolomics; 2012 Feb; 8(1):109-119. PubMed ID: 22279428
[TBL] [Abstract][Full Text] [Related]
17. Extracellular vesicles metabolic changes reveals plasma signature in stage-dependent diabetic kidney disease.
Pan Y; Yang H; Chen T; Jin J; Ruan L; Hu L; Chen L
Ren Fail; 2022 Dec; 44(1):1840-1849. PubMed ID: 36368309
[TBL] [Abstract][Full Text] [Related]
18. Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol.
Gooding KM; Lienczewski C; Papale M; Koivuviita N; Maziarz M; Dutius Andersson AM; Sharma K; Pontrelli P; Garcia Hernandez A; Bailey J; Tobin K; Saunavaara V; Zetterqvist A; Shelley D; Teh I; Ball C; Puppala S; Ibberson M; Karihaloo A; Metsärinne K; Banks RE; Gilmour PS; Mansfield M; Gilchrist M; de Zeeuw D; Heerspink HJL; Nuutila P; Kretzler M; Welberry Smith M; Gesualdo L; Andress D; Grenier N; Shore AC; Gomez MF; Sourbron S;
BMC Nephrol; 2020 Jun; 21(1):242. PubMed ID: 32600374
[TBL] [Abstract][Full Text] [Related]
19. Association of urinary acidification function with the progression of diabetic kidney disease in patients with type 2 diabetes.
Zhu H; Liu X; Zhang C; Li Q; An X; Liu S; Wu L; Zhang B; Yuan Y; Xing C
J Diabetes Complications; 2019 Nov; 33(11):107419. PubMed ID: 31473080
[TBL] [Abstract][Full Text] [Related]
20. Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease.
Liu JJ; Ghosh S; Kovalik JP; Ching J; Choi HW; Tavintharan S; Ong CN; Sum CF; Summers SA; Tai ES; Lim SC
Kidney Int Rep; 2017 May; 2(3):470-480. PubMed ID: 29142974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
